company background image
NAOV logo

NanoVibronix NasdaqCM:NAOV Stock Report

Last Price

US$0.93

Market Cap

US$1.9m

7D

3.5%

1Y

-74.2%

Updated

27 Mar, 2024

Data

Company Financials

NAOV Stock Overview

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.

NAOV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NanoVibronix, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NanoVibronix
Historical stock prices
Current Share PriceUS$0.93
52 Week HighUS$4.34
52 Week LowUS$0.72
Beta1.26
1 Month Change-8.62%
3 Month Change-22.33%
1 Year Change-74.18%
3 Year Change-95.43%
5 Year Change-98.83%
Change since IPO-98.67%

Recent News & Updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Dec 09
Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Oct 19

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

Sep 23

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Jul 08
Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Mar 22
Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

Dec 01
Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

NanoVibronix: Portable Ultrasonic Therapeutic Devices

Sep 01

NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

Aug 17
NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

NanoVibronix announces expansion of distribution pact for its ultrasound devices

Dec 11

NanoVibronix secures $6M in equity capital

Dec 02

NanoVibronix reports Q3 results

Nov 17

Shareholder Returns

NAOVUS Medical EquipmentUS Market
7D3.5%2.2%0.4%
1Y-74.2%13.3%28.8%

Return vs Industry: NAOV underperformed the US Medical Equipment industry which returned 12% over the past year.

Return vs Market: NAOV underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is NAOV's price volatile compared to industry and market?
NAOV volatility
NAOV Average Weekly Movement10.4%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: NAOV's share price has been volatile over the past 3 months.

Volatility Over Time: NAOV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200312Brian Murphyhttps://www.nanovibronix.com

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.

NanoVibronix, Inc. Fundamentals Summary

How do NanoVibronix's earnings and revenue compare to its market cap?
NAOV fundamental statistics
Market capUS$1.91m
Earnings (TTM)-US$4.96m
Revenue (TTM)US$1.00m

1.9x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NAOV income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$504.00k
Gross ProfitUS$500.00k
Other ExpensesUS$5.46m
Earnings-US$4.96m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.42
Gross Margin49.80%
Net Profit Margin-493.73%
Debt/Equity Ratio0%

How did NAOV perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.